compounding semaglutide pharmacy title π¨ Important Update on Compounded GLP-1 Injectables π¨ The FDA has announced that the shortage is resolved, requiring all 503A pharmacies to stop and dispensing injectable semaglutide by April IvΓm Health | Compounded Semaglutide
Description
Serious kidney problems from GLP-1 therapy are rare, but vomiting, diarrhea, and dehydration may impair kidney function in the short term
10.1152/ajpendo.1997.273.5.E981
Short excursions are fine
Retatrutide also may stimulate lipolysis in fat tissue through the activation of GIP receptors
This is to allow elimination of the glucocorticoid to below the reporting level
22, e13210
